Publications by authors named "E Dios Sanz"

Objective: The objective of this study was to determine the physicochemical and microbiological stability of a 0.5% aqueous oral solution of methadone for dispensing to Drug Dependency Centers in the Region of Murcia.

Materials And Methods: Six different batches of 5 L methadone 0.

View Article and Find Full Text PDF
Article Synopsis
  • Clozapine use is primarily associated with the risk of neutropenia, but there is limited research on adverse drug reactions (ADRs) and fatal outcomes in patients under 18 years old.
  • A study analyzed 2,825 reports of clozapine usage in this age group, revealing 42 fatal outcomes, with the most common ADR being decreased white blood cell count, while suicide was a significant cause of non-duplicated fatalities.
  • To better prevent fatal outcomes in young patients, child and adolescent psychiatrists should broaden their focus beyond severe neutropenia to include other serious ADRs like pneumonia, while still being cautious of the risk of overdose in those at risk for suicide.
View Article and Find Full Text PDF

Background: Despite efforts to improve undergraduate clinical pharmacology & therapeutics (CPT) education, prescribing errors are still made regularly. To improve CPT education and daily prescribing, it is crucial to understand how therapeutic reasoning works. Therefore, the aim of this study was to gain insight into the therapeutic reasoning process.

View Article and Find Full Text PDF

The calculation of the interfacial free energy between two thermodynamic phases is crucial across various fields, including materials science, chemistry, and condensed matter physics. In this study, we apply an existing thermodynamic approach, the Gibbs-Cahn integration method, to determine the interfacial free energy under different coexistence conditions, relying on data from a single-state calculation at specified pressure and temperature. This approach developed by Laird et al.

View Article and Find Full Text PDF

Purpose: Clozapine is an antipsychotic which was approved in 1989 for treatment-resistant schizophrenia in the United States (US). There were few randomized trials before its approval and potentially lethal clozapine adverse drug reactions (ADRs), such as agranulocytosis and myocarditis were identified by pharmacovigilance. VigiBase, the WHO global database, is a cornerstone of international pharmacovigilance efforts for ADR identification during post-marketing surveillance.

View Article and Find Full Text PDF